It's hard to ignore how far DAL has run over the past year. Just scanning back, it was sitting around 48 back in June last year, and now it's suddenly at 80.02. That's a huge ramp, especially with a few sharp jumps this winter. The airline sector always gets some cyclical tailwinds, but this feels a bit stretched. I'd say the broader move is justified by pent up demand and some decent cost controls, but the easy money has probably already been made.
I'm leaning bearish here, not because the company is falling apart, but because valuation's getting ahead of itself. At 80, this is pricing in a lot of perfection. One thing that stands out is fuel costs if there's a surprise there, margins can compress fast. Also, competition on international routes is ramping up and fares aren't as sticky as people think when everyone wants to fill planes. My target is 68.00, so I'm expecting a pullback of about 15 percent from here, mostly on multiple contraction as the travel boom chills out or if we get any softening in bookings this summer.
I do see one catalyst that could keep the price supported in the short run: the upcoming earnings release. If DAL posts another strong quarter with guidance that's upbeat (and not just rosy headlines), maybe it holds up a bit longer. But any whiff of uncertainty, or if costs are ticking up again, I don't see the current valuation holding.
Risks to a bearish play? If oil prices drop sharply or there's some positive shock for airlines (giant buybacks, regulatory change), this could squeeze even higher. So I'd watch position sizing carefully and not overcommit until the trend actually turns.
MDT has been on a rough slide for months. Just last November it was over 100, and now it's scraping $73.81. That's a big drawdown, and from looking at the price history, it's been a pretty steady downward trend since about February. There's a risk in thinking it's "cheap" just because it's near the year's low, but I'm not rushing to call a bottom either.
Bullish case for me is pretty simple: Medtronic still throws off cash, and the dividend's not at risk. They haven't had major negative surprises on the fundamentals side, more just a general drag from slower elective procedures and some headwinds in China. The company's been investing in new product lines (the diabetes CGM business could move the needle if management executes) and their scale gives them some margin safety if healthcare spending rebounds.
That said, the clear risk is dead money for a while. If US hospital procedure volumes don't pick up, or if their diabetes pipeline slips even a quarter, there's probably a lot more sideways than up. Also, it's hard to ignore how weak the stock's been bouncing from $90s to mid 70s in under six months isn't just macro noise. Could be some fund outflows or rotating away from sleepy medtech, so don't expect a quick pop.
The near term catalyst I'm watching is their next earnings call. If they can show any progress on the diabetes launch narrative or guide a little better on margins, I think you'll see a relief bounce. My target's pretty modest I'm looking for a move back to $83.00 over the next 12 weeks. Not shooting for the moon, just a grind higher if they can settle the story a bit.
Looking at CL and where it's trading at 91.29 right now, I'm leaning bearish overall. Just glancing at the past year, there's been a lot of chop. The stock dropped from the low 90s last summer to a bottom in the mid 70s by November, then it managed a pretty sharp run back above 97 in February and March. But since then, it's drifted down again and hasn't really found steady ground.
The main issue I see is that after that quick spike in early 2026, the move proved unsustainable. CL hasn't managed to build on that momentum and is basically back in the same range as last fall. There's clearly demand for their products, but cost pressures and a sluggish consumer environment make it tough for them to expand margins. I'm not expecting any major upside surprise in the near term.
That said, this isn't a disaster scenario just not a growth story right now. Maybe the best case is some cost efficiencies or mild price increases, but those seem mostly priced in after the rebound earlier this year. If inflation ticks up again or we get a weak quarter, CL could drift back to 83.00. That's my target. I'm not calling for a collapse, just a return to the lower end of its recent channel.
The big risk here is an unexpected uptick in consumer spending or a major cost breakthrough for them. If that happens, I could see being too pessimistic. Next earnings will be the main catalyst if they guide down or keep it cautious, I think this slides toward my target.
Looking at DXCM at 72.10, things feel a little shaky underneath the surface. You can see in the price action over the past year: DXCM has been tossed around from highs near 89 in late summer last year all the way down to lows around 59 in November. Even more recently, we saw a rebound to about 74 in late Jan, but it's still a choppy ride. That kind of volatility usually makes me pause before getting too excited.
I lean bullish here, but not by a wide margin. My target is 81.00. The main thing that keeps me interested is that, despite all the swings, management has kept revenue growth pretty solid quarter to quarter. CGM (continuous glucose monitoring) adoption still looks like it's got room to run, and their tech has actual staying power at least compared to some of their competitors. Margins have also held up better than I expected, especially given all the supply chain headwinds last year.
But there's a real risk that pricing pressure comes in harder than people anticipate, especially if insurers start pushing back. That's not something you can just ignore if payers squeeze them, it cuts right into their expansion case. Also worth flagging that the market seems skittish any time guidance gets tweaked, so no one should get too comfortable here.
The next big move could come with the Q2 results. If they can show not just user growth but some stabilization in ASPs (average selling prices), I think the stock could get a bump. But I’m keeping a tight leash on this one if the business starts to wobble, I’d rather step aside than try to outsmart a falling knife.
DE's chart is giving me some mixed feelings right now. For the first half of the year, it looked rough, consistently trending down from over 500 to below 470 at one point. Then the story flipped February saw a breakout well past 600, with a short lived spike up to 644 before it settled back in the high 500s. That bounce makes me a bit wary we could be looking at a double top situation, or at minimum, a lot of churn ahead.
Still, I lean cautiously bullish in the near term. The company should see some tailwinds from continued infrastructure demand and a decent crop season. Orders look steady even if they're not explosive, and there's not much sign of a collapse in ag spending. My view is the stock can claw its way up to 610.00 over the next couple months if things break right, which is just under 9% from here.
I'm not ignoring the big risks, though. If rates stay elevated or we get a weak macro print, I'd expect industrials like DE to get clipped fast. There's also some concern on inventory build if channel stuffing shows up in the next report, this could rewind quickly. I don't see much reason to back up the truck at this price, but if you want some exposure, scaling in slowly seems safest.
As for catalysts, watch how the upcoming earnings call handles guidance for the rest of the year. Any surprise uptick in orders or better margin commentary could be the nudge this needs to break out again. But I'm not betting on a runaway rally just a slow grind higher unless the tone really shifts.
That chart for HUBS is just rough. From $660+ last May down to sub $250 now there’s no sugarcoating it. I’m leaning bearish here with a target of $165.00 and won’t pretend the freefall is just because of one bad quarter. It’s been a steady decline with a few minor bounces along the way, but nothing to reverse the bigger trend.
There are a couple things that really make me nervous. First, the multiple compression isn’t just about the market. After that big re rating last August, HUBS hasn’t shown much to justify a higher valuation. Top line growth keeps slowing, and even though they’ve been pushing new features, they’re not translating into stronger numbers. Churn is creeping up, and their core SMB customers are probably still feeling the squeeze. I also just don’t see enough operational leverage to weather another macro hiccup.
Sure, maybe they could surprise with a cost cut announcement or some M&A talk, but that would be a short term pop at best. For the bulls, the main thing to watch is their next earnings report if they can hold the line on margins and show user growth isn’t rolling over, it could get interesting. But right now, too much risk for not enough reward.
The wild card is always some kind of acquisition or activist catalyst, but that’s not a bet I want to make at this price. For now, I see more downside before it finds a floor. If anything changes, happy to revisit, but not catching this one until I see a real sign of stability.
AVGO has had a pretty wild year if you look at the price action. It went from the low 230s last May all the way up to 425 just recently. That's a big ride for anyone holding through the volatility. But right now at 416.79, I'm leaning bearish over the next few months. The rapid run up from below 320 in March to over 425 last week is a red flag for me. That kind of move rarely holds up unless something fundamental has really changed, and I don't see a big enough shift in Broadcom's core business to justify it.
My target is 375.00. I think we see a retrace as some of the hype wears off. Broadcom's still got strengths (recurring revenue, strong customer ties), but a lot looks priced in and then some. Margins are steady but haven't really expanded, and the big catalyst that could push it higher just isn't obvious right now. The last few quarters have been "fine" but not blowout. If they guide down or even just keep the outlook unchanged, I expect sellers to step in.
One big risk in the other direction: if they announce a major design win or something truly surprising (acquisition, big beat), this thing can squeeze hard given how much attention it's gotten. But that's not the base case for me. The next earnings call is the real catalyst to watch here.
So in short, I'm cautious leaning bearish, and think 375 is more reasonable in the next couple of months unless there's a material upside surprise.
HD’s had a pretty rough go over the past year. Looking at the price trend, it was trading up at 420+ last September, but since then it’s been mostly downhill, especially after the start of the year. Now at 317.45, it’s back near its 52 week lows. I think that’s a sign caution is warranted. It might be tempting to call a bottom here, but I’m not convinced this is a screaming buy just yet.
My stance is mildly bullish, with a target of 355.00, so I’m expecting a modest recovery. There are two main reasons for that. First, I think the fear around the ongoing weakness in consumer discretionary spending is a bit overdone. Home Depot still has steady pro contractor business and their dividend is reliable. Second, management has been good about cost control you can see it in how they’ve held up margins even as revenue has softened.
The catch here is macro risk. If we get a surprise move in rates, or if the housing market stays sluggish into the summer, HD could drift sideways or even retest recent lows. I’m not expecting much excitement until we get some clarity on interest rates, but if mortgage rates start to ease, that’s the next real catalyst for Home Depot to break out of this funk.
So overall, I think there’s a cautious case to pick up shares under 320 and look for a move to 355.00 over the next few months, but you really have to be patient here. Nothing explosive, just a reasonable shot at some upside once the macro picture gets less murky.
Looking at PEG right now, I don’t see a ton of immediate upside. It's sitting at 77.83 which is actually near the lower end of its past year's range. Over the last 12 months, the stock has bounced around the low 80s, even touching 87 at one point last summer, but it’s usually snapped right back down. This is a pretty clear signal to me that the market just isn't willing to give it a premium, at least not yet. Utilities can be defensive, but PEG is really just treading water.
Any optimism here comes from recent regulatory filings that cleared up some overhang around future rate hikes. That helps earnings visibility a bit. There’s also consistent dividend support, which makes holding PEG less painful while you wait for something to actually move the price. But I’m not expecting much growth. The region’s demand is about as stable as it gets, but the flip side is it’s not going to save you with surprises.
Biggest risk is new costs if weather events or grid upgrades hit harder than management forecasts. That’s always on the table, and I worry that’s not fully baked in. I also think any catalyst is likely to be pretty slow. If we see some clarity on transmission investments or a cleaner path to recover those costs from regulators, that could nudge PEG up a bit this quarter.
Bullish is maybe too strong, but I do think fair value sits closer to 85.50 in the next 10 weeks. Not a rocket ship, but if you want a patient hold with a bit of yield and low drama, PEG fits.
Looking at PYPL lately, it's been pretty tough to get excited. The price action over the last year makes the story pretty clear: from highs near 76 last summer to a sharp dump below 41 in early February, and now a partial rebound up to around 51. That's a lot of volatility for what's supposed to be a large, established payments business. It's tempting to see this as a value play but the market is clearly still sorting out what PYPL is worth now that growth has cooled off so much.
Still, at 50.94, I think there's some cautious upside here. PayPal's core business is profitable, and they've finally started to rein in expenses. The competitive pressure from Apple Pay and the BNPL crowd doesn't seem to be letting up, but PayPal is leaning into cost efficiency and so far hasn't lost a huge chunk of market share. If they keep focusing on transaction margin and improve their checkout product even a little, I could see a gradual rerating.
My target is 60.00. That would mean a bit of multiple recovery and some operational improvement not a return to past glory, just a less discounted take. I don't see a sudden catalyst but I'm watching the next earnings for signs of stabilization in user growth. If they can show flat to slightly up active accounts and some traction with new fee initiatives, it could get a relief rally.
Biggest risk is that the competitive moat keeps shrinking and management overpromises on the turnaround. Every "new" strategy is under a microscope now. If the next guide is weak or the board fumbles communication again, this could be dead money for a while. Not a hero trade, just a slow grind up if things go right.
